Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes
Kershaw V. Patel(Houston Methodist), Ambarish Pandey(The University of Texas Southwestern Medical Center), Chiadi E. Ndumele, Antoni Bayés‐Genís(Universitat Autònoma de Barcelona), James A. de Lemos(The University of Texas Southwestern Medical Center), Christie M. Ballantyne(Manpower Demonstration Research Corporation), Zainali Chunawala(Southwestern Medical Center), Mark A. Espeland(Wake Forest University), Javed Butler(Emory University), Subodh Verma(University of Toronto), Thomas J. Wang(Agricultural Research Service), Katelyn R Garcia(Wake Forest University), James L. Januzzi(Harvard University), Alain G. Bertoni(Wake Forest University), Carolyn S.P. Lam(National University of Singapore), Matthew W. Segar
Cited by 12
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k